{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:00:52Z","timestamp":1787666452277,"version":"build-2736575974"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>SGLT-2 inhibitors (SGLT-2i) and GLP-1 receptor agonists (GLP-1 RA) are two widely used classes of medications in the treatment of diabetes, each demonstrating significant efficacy and adoption. These medications have shown promising results in glycemic control and offer additional health benefits such as weight loss and cardiovascular protection. The objective of our meta-analysis is to systematically assess the effectiveness of SGLT-2 inhibitors and GLP-1 receptor agonists in slowing down or preventing the progression of prediabetic patients into diabetics. By synthesizing the existing evidence, we aim to determine whether early intervention with these medications can effectively mitigate the risk of developing diabetes in prediabetic individuals. This analysis will provide critical insights into their comparative effectiveness and inform clinical decision-making for early diabetes prevention strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this meta-analysis we primarily focused on randomized control trials (RCTs) that included the use of either SGLT-2 inhibitors, GLP-1 receptor agonists, or both. The database search was conducted using PubMed, Embase, and Cochrane. Statistical analysis was performed using IBM SPSS, and the results were reported with a 95% confidence interval (CI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The meta-analysis included 14 studies with the majority being double blinded (13\/14). Effective randomization was evident from balanced baseline characteristics between treatment and control groups. Both SGLT-2 inhibitors and GLP-1 receptor agonists demonstrated significant reductions in body weight when given individually. This effect is also amplified when given as a combination therapy (SMD: -23, 95% CI: [-27.9, -18.10]). Also, fasting plasma glucose levels decreased in patients receiving treatment (SMD: -5.40, 95% CI: [-10.70, 2.24]) compared to control groups. Moreover, HbA1c levels were assessed in seven studies, where significant reductions in treatment groups were reported with a standardized mean difference of -6.95 (95% CI: [-14.24, 2.98], p-value= 0.06) for the overall effect size. Furthermore, three studies showed that SGLT-2 inhibitors reduced diabetes mellitus (DM) onset, though statistical significance was not achieved (p-value = 0.08, SMD: -2.21, CI: [-5.11, 0.69]). Finally, no significant change in fasting insulin levels was noticed with an overall SMD of -1.74 (95% CI: [-6.84, 3.37]), which was also not statistically significant (p-value: 0.55). These findings highlight the efficacy of SGLT-2 inhibitors and GLP-1 receptor agonists in reducing HbA1C, fasting blood glucose, and body weight, while also potentially delaying the progression to type 2 diabetes mellitus in prediabetic patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Early medical intervention at the prediabetic stage with SGLT-2i or GLP-1 RA shows potential in modifying progression to the onset of T2DM and its adverse effects. However, more studies are needed to reliably assess which of the two yields better results and further investigate the potential of combination therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:uri>\n                      , identifier CRD42024565439.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1627909","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T04:12:55Z","timestamp":1761192775000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["GLP1 receptor agonists and SGLT2 inhibitors for the prevention or delay of type 2 diabetes mellitus onset: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Farah","family":"Ghobar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Tarhini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeinab","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Sbeih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph Abou","family":"Ghayda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patena","family":"Matar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaelle","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amjad","family":"Kanaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assaad","family":"Eid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Azar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilda E.","family":"Ghadieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Harb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1152\/physiol.00003.2018","article-title":"Circadian etiology of type 2 diabetes mellitus","volume":"33","author":"Javeed","year":"2018","journal-title":"Physiology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1146\/annurev-publhealth-090419-102644","article-title":"Prediabetes and what it means: the epidemiological evidence","volume":"42","author":"Echouffo-Tcheugui","year":"2021","journal-title":"Annu Rev Public Health"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2522\/ptj.20080008","article-title":"Diabetes-related microvascular and macrovascular diseases in the physical therapy setting","volume":"88","author":"Cade","year":"2008","journal-title":"Phys Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051013-110046","article-title":"The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus","volume":"66","author":"Vallon","year":"2015","journal-title":"Annu Rev Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"B7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.15277\/bjdvd.2015.011","article-title":"The use of GLP-1 agonist therapy, liraglutide, is associated with significant weight loss in morbidly obese people without diabetes","volume":"15","author":"Gillani","year":"2015","journal-title":"Br J Diabetes"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15113","article-title":"Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes","volume":"25","author":"Silver","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.2001.281.1.E155","article-title":"Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers","volume":"281","author":"Edwards","year":"2001","journal-title":"Am J Physiol.-Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.059785","article-title":"Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes","volume":"146","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"B11","doi-asserted-by":"publisher","first-page":"398","DOI":"10.2337\/dc21-1136","article-title":"Empagliflozin improves insulin sensitivity of the hypothalamus in humans with prediabetes: A randomized, double-blind, placebo-controlled, phase 2 trial","volume":"45","author":"Kullmann","year":"2022","journal-title":"Diabetes Care"},{"key":"B12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s00125-020-05306-1","article-title":"The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial","author":"F\u00e6rch","year":"2021","journal-title":"Diabetologia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-1675","article-title":"Dapagliflozin and the incidence of type 2 diabetes in patients with heart failure and reduced ejection fraction: an exploratory analysis from DAPA-HF","volume":"44","author":"Inzucchi","year":"2021","journal-title":"Diabetes Care"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2022.155396","article-title":"Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: A randomized, double-blind crossover trial","volume":"140","author":"Veelen","year":"2023","journal-title":"Metabolism"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051824","article-title":"Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status","volume":"143","author":"Anker","year":"2021","journal-title":"Circulation"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14242","article-title":"Effect of the glucagon-like peptide-1 analogue liraglutide versus placebo treatment on circulating proglucagon-derived peptides that mediate improvements in body weight, insulin secretion and action: A randomized controlled trial","volume":"23","author":"Kim","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/acps.12982","article-title":"One-year follow-up on liraglutide treatment for prediabetes and overweight\/obesity in clozapine- or olanzapine-treated patients","volume":"139","author":"Svensson","year":"2019","journal-title":"Acta Psychiatr Scand"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2014.177","article-title":"Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss","volume":"39","author":"Iepsen","year":"2015","journal-title":"Int J Obes"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e12432","DOI":"10.1111\/cob.12432","article-title":"Efficacy and safety of glucagon-like peptide-1\/glucagon receptor co-agonist JNJ -64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose-ranging study","volume":"11","author":"Alba","year":"2021","journal-title":"Clin Obes"},{"key":"B20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/dom.12779","article-title":"Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes","volume":"19","author":"Lundkvist","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/MBP.0000000000000479","article-title":"Effects of dapagliflozin on blood pressure variability in patients with prediabetes and prehypertension without pharmacological treatment: a randomized trial","volume":"25","author":"D\u00edaz-Cruz","year":"2020","journal-title":"Blood Press Monit"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1055\/a-0664-7583","article-title":"Effect of dapagliflozin on insulin secretion and insulin sensitivity in patients with prediabetes","volume":"128","author":"Ram\u00edrez-Rodr\u00edguez","year":"2020","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22854","article-title":"Effects of empagliflozin treatment on glycerol-derived hepatic gluconeogenesis in adults with obesity: A randomized clinical trial","volume":"28","author":"Neeland","year":"2020","journal-title":"Obesity"},{"key":"B24","volume-title":"IDF diabetes atlas","year":""},{"key":"B25","unstructured":"Type 2 diabetes mellitus: Prevalence and risk factors\n          \n          \n            \n              Robertson\n              RP\n            \n            \n              Lipska\n              KJ"},{"key":"B26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","article-title":"Epidemiology of type 2 diabetes \u2013 global burden of disease and forecasted trends","volume":"10","author":"Khan","year":"2019","journal-title":"J Epidemiol Glob Health"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1001\/jamainternmed.2017.6040","article-title":"Long-term sustainability of diabetes prevention approaches: A systematic review and meta-analysis of randomized clinical trials","volume":"177","author":"Haw","year":"2017","journal-title":"JAMA Intern Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cmet.2021.12.012","article-title":"Why does obesity cause diabetes","volume":"34","author":"Klein","year":"2022","journal-title":"Cell Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1627909\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T04:12:56Z","timestamp":1761192776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1627909\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":28,"alternative-id":["10.3389\/fendo.2025.1627909"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1627909","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"article-number":"1627909"}}